About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Pharmaceuticals
- Exchange: NASDAQ
- Symbol: NKTR
- CUSIP: 64026810
- Previous Close: $13.10
- 50 Day Moving Average: $12.72
- 200 Day Moving Average: $14.89
- 52-Week Range: $152,835,000.00 - $10.52
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -15.60
- P/E Growth: 1.66
- Market Cap: $2.00B
- Outstanding Shares: 152,835,000
- Beta: 1.84
- Net Margins: -98.87%
- Return on Equity: -8,769.15%
- Return on Assets: -35.17%
Companies Related to Nektar Therapeutics:
- Debt-to-Equity Ratio: -3.61%
- Current Ratio: 3.70%
- Quick Ratio: 3.56%
What is Nektar Therapeutics' stock symbol?
Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."
Where is Nektar Therapeutics' stock going? Where will Nektar Therapeutics' stock price be in 2017?
5 brokerages have issued 12-month price targets for Nektar Therapeutics' shares. Their predictions range from $15.00 to $25.00. On average, they expect Nektar Therapeutics' share price to reach $21.20 in the next twelve months.
When will Nektar Therapeutics announce their earnings?
Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns Nektar Therapeutics stock?
Nektar Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (2.66%), Janus Capital Management LLC (1.17%), FMR LLC (0.89%), Federated Investors Inc. PA (0.67%), Two Sigma Investments LP (0.66%) and Marshall Wace LLP (0.54%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Stephen K Doberstein and Susan Wang.
Who sold Nektar Therapeutics stock? Who is selling Nektar Therapeutics stock?
Nektar Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Oxford Asset Management, Dimensional Fund Advisors LP, Allianz Asset Management AG, Janus Capital Management LLC, Guggenheim Capital LLC, Pacad Investment Ltd. and AQR Capital Management LLC. Company insiders that have sold Nektar Therapeutics stock in the last year include Christopher A Kuebler, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Robert Chess and Stephen K Doberstein.
Who bought Nektar Therapeutics stock? Who is buying Nektar Therapeutics stock?
Nektar Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Two Sigma Investments LP, Marshall Wace LLP, J. Goldman & Co LP, Advisory Research Inc., Highland Capital Management LP, Russell Investments Group Ltd. and Systematic Financial Management LP.
How do I buy Nektar Therapeutics stock?
Shares of Nektar Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Nektar Therapeutics stock cost?
One share of Nektar Therapeutics stock can currently be purchased for approximately $13.10.